Work

Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.8523

Authors: Alex K. Bryant, Huiying Yin, Matthew J. Schipper, Peter Alexander Paximadis, Thomas Pence Boike, Derek P. Bergsma, Benjamin Movsas, Munther Isa Ajlouni, Robert Timothy Dess, Melissa A. Mietzel, Randi Kendrick, Merita Seferi, Michael M. Dominello, Martha Matuszak, Reshma Jagsi, James Hayman, Lori J. Pierce, Shruti Jolly

Institutions: University of Michigan, U-M Rogel Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Detroit Medical Center, Henry Ford Hospital, Henry Ford Health

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDGs: Good health and well-being, Reduced inequalities

Open Access status: closed

OpenAlex ID: W3171765007

Cites:

Cited by:

Related to: 10